Nascent Biotech, Inc. (NBIO)
USD 0.01
(44.44%)
USD 0.01
(44.44%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -2.08 Million USD | 25.47% |
| 2023 | -2.8 Million USD | -1796.33% |
| 2022 | -147.7 Thousand USD | 88.77% |
| 2021 | -1.31 Million USD | 67.86% |
| 2020 | -4.09 Million USD | -198.84% |
| 2019 | -1.36 Million USD | 38.37% |
| 2018 | -2.22 Million USD | -295.38% |
| 2017 | 1.13 Million USD | 127.4% |
| 2016 | -4.14 Million USD | -92.77% |
| 2015 | -2.15 Million USD | -12.22% |
| 2014 | -1.91 Million USD | -178.31% |
| 2013 | -689.1 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -512.57 Thousand USD | -149.54% |
| 2024 Q3 | -205.4 Thousand USD | 75.24% |
| 2024 Q1 | -540.22 Thousand USD | -4.28% |
| 2024 FY | -2.08 Million USD | 25.47% |
| 2024 Q2 | -829.47 Thousand USD | -53.54% |
| 2023 Q2 | 229.8 Thousand USD | 117.68% |
| 2023 Q1 | -1.29 Million USD | -259.71% |
| 2023 FY | -2.8 Million USD | -1796.33% |
| 2023 Q4 | -518.05 Thousand USD | 56.81% |
| 2023 Q3 | -1.19 Million USD | -622.02% |
| 2022 Q2 | -211.03 Thousand USD | 53.11% |
| 2022 FY | -147.7 Thousand USD | 88.77% |
| 2022 Q1 | -450.07 Thousand USD | -217.51% |
| 2022 Q3 | 597.32 Thousand USD | 383.05% |
| 2022 Q4 | -361.36 Thousand USD | -160.5% |
| 2021 Q2 | -418.29 Thousand USD | -105.08% |
| 2021 Q1 | -203.97 Thousand USD | 93.26% |
| 2021 FY | -1.31 Million USD | 67.86% |
| 2021 Q4 | 383 Thousand USD | 153.23% |
| 2021 Q3 | -719.5 Thousand USD | -72.01% |
| 2020 FY | -4.09 Million USD | -198.84% |
| 2020 Q3 | -370.15 Thousand USD | -11.54% |
| 2020 Q2 | -331.85 Thousand USD | -21.23% |
| 2020 Q1 | -273.73 Thousand USD | 18.2% |
| 2020 Q4 | -3.02 Million USD | -718.15% |
| 2019 Q1 | -439.71 Thousand USD | 45.12% |
| 2019 Q4 | -334.62 Thousand USD | -30.43% |
| 2019 Q3 | -256.56 Thousand USD | 24.09% |
| 2019 FY | -1.36 Million USD | 38.37% |
| 2019 Q2 | -337.99 Thousand USD | 23.13% |
| 2018 Q1 | -298.18 Thousand USD | 35.71% |
| 2018 Q2 | -558.19 Thousand USD | -87.2% |
| 2018 Q3 | -563.62 Thousand USD | -0.97% |
| 2018 FY | -2.22 Million USD | -295.38% |
| 2018 Q4 | -801.29 Thousand USD | -42.17% |
| 2017 Q3 | -567.81 Thousand USD | -137.97% |
| 2017 FY | 1.13 Million USD | 127.4% |
| 2017 Q4 | -463.84 Thousand USD | 18.31% |
| 2017 Q2 | 1.49 Million USD | 122.24% |
| 2017 Q1 | 672.97 Thousand USD | 190.4% |
| 2016 Q1 | -796.49 Thousand USD | 14.96% |
| 2016 Q4 | -744.47 Thousand USD | -119.46% |
| 2016 Q3 | -339.22 Thousand USD | 85.05% |
| 2016 FY | -4.14 Million USD | -92.77% |
| 2016 Q2 | -2.26 Million USD | -184.82% |
| 2015 Q2 | -328.25 Thousand USD | -41.55% |
| 2015 FY | -2.15 Million USD | -12.22% |
| 2015 Q1 | -231.9 Thousand USD | 37.55% |
| 2015 Q3 | -655.35 Thousand USD | -99.65% |
| 2015 Q4 | -936.61 Thousand USD | -42.92% |
| 2014 Q3 | -1.4 Million USD | -1773.09% |
| 2014 Q2 | -74.95 Thousand USD | -5.15% |
| 2014 FY | -1.91 Million USD | -178.31% |
| 2014 Q4 | -371.36 Thousand USD | 73.55% |
| 2014 Q1 | -71.28 Thousand USD | 0.0% |
| 2013 FY | -689.1 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -56.33% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 70.103% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.941% |
| Rebus Holdings, Inc. | -1.02 Million USD | -104.675% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.205% |
| Qrons Inc. | -789.34 Thousand USD | -164.482% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -230.117% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 96.665% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -402.476% |
| Skye Bioscience, Inc. | -37.64 Million USD | 94.454% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.215% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 68.254% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -663.594% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.373% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 27.822% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -14.675% |
| Mesoblast Limited | -87.95 Million USD | 97.626% |
| Marizyme, Inc. | -65.34 Million USD | 96.805% |
| Genus plc | 7.9 Million USD | 126.426% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 80.832% |
| Pharming Group N.V. | -10.54 Million USD | 80.208% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 3.785% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 43.732% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 76.394% |
| ContraFect Corporation | -65.15 Million USD | 96.796% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 57.273% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -20.853% |
| IMV Inc. | -36.48 Million USD | 94.278% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 74.097% |
| MultiCell Technologies, Inc. | -380.07 USD | -549188.815% |
| ONE Bio Corp. | 8.67 Million USD | 124.061% |
| Accustem Sciences Inc. | -3.74 Million USD | 44.275% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 95.961% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -64.756% |
| Q BioMed Inc. | -2.05 Million USD | -1.734% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 44.075% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 12.314% |
| Biomind Labs Inc. | -1.21 Million USD | -71.922% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.505% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 32.694% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 73.584% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -7.102% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -13840.184% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 86.846% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 64.112% |
| GB Sciences, Inc. | -1.36 Million USD | -53.317% |
| Alpha Cognition Inc. | -13.77 Million USD | 84.842% |
| HST Global, Inc. | -146.21 Thousand USD | -1327.865% |
| CSL Limited | 2.64 Billion USD | 100.079% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -18.972% |
| Halberd Corporation | -79.67 Thousand USD | -2520.214% |
| Enzolytics Inc. | -2.17 Million USD | 4.095% |
| Agentix Corp. | -1.37 Million USD | -51.919% |
| Resverlogix Corp. | -3.61 Million USD | 42.169% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 34.172% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.292% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2230.288% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 130.149% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 47.453% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 31.012% |
| AVAX Technologies, Inc. | -6.41 Million USD | 67.449% |
| Zenith Capital Corp. | -10.59 Million USD | 80.297% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.813% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -8882.368% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 49.645% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -3354.105% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -4.118% |
| Kadimastem Ltd | -3.3 Million USD | 36.878% |
| Helix BioMedix, Inc. | -1.05 Million USD | -97.686% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 45.334% |
| BioStem Technologies, Inc. | -8.48 Million USD | 75.39% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -373.002% |
| LadRx Corporation | 400.44 Thousand USD | 621.343% |
| Cell Source, Inc. | -5.32 Million USD | 60.767% |
| Regen BioPharma, Inc. | 1.02 Million USD | 303.973% |
| Regen BioPharma, Inc. | 1.02 Million USD | 303.973% |
| NovAccess Global Inc. | -4.76 Million USD | 56.226% |
| Affymax, Inc. | -14.42 Million USD | 85.526% |
| Itoco Inc. | -1.86 Million USD | -11.701% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 53.007% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -25.086% |
| Mobile Lads Corp. | -2.26 Million USD | 7.759% |
| CytoDyn Inc. | -49.84 Million USD | 95.811% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2541.532% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -815.14% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -121.733% |
| SYBLEU INC | -180.3 Thousand USD | -1057.868% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -29.45% |
| International Stem Cell Corporation | -131 Thousand USD | -1493.65% |
| Bioxytran, Inc. | -4.28 Million USD | 51.222% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3746.702% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 17.491% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 95.657% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 1.245% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -167.348% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 34.101% |
| Neutra Corp. | -233.46 Thousand USD | -794.216% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 89.711% |
| PureTech Health plc | -65.69 Million USD | 96.822% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 90.183% |
| IXICO plc | -1.17 Million USD | -77.223% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 78.97% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.346% |
| CSL Limited | 2.64 Billion USD | 100.079% |
| Cellectis S.A. | -103.17 Million USD | 97.977% |